May. 4 at 7:10 PM
TOM BRADY ! investor / spokesman new competitor for
$LLY
Linda Yaccarino’s GLP-1 telehealth unicorn raises
$200M on adherence claim that bucks industry norm
EMed secures Series A at a
$2B valuation. But will its adherence rate hold up at scale?
... atest claim that its users’ GLP-1 adherence rate exceeds 90%.
This rate would be remarkable by industry standards when applied at scale.
“The high adherence rates claimed by eMed lack the peer-reviewed, clinical validation warranted for numbers that deviate so drastically from established norms in the GLP-1 space,” said Ben Zercher, senior biotech and pharma analyst at PitchBook.
raised the Series A round at a
$2 billion valuation. Led by AON Consulting, backers in the latest round included former NFL quarterback Tom Brady, Valor Equity Partners CEO Antonio Gracias, and 8VC managing partner Joe Lonsdale.
